Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Research & Development (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Research & Development for 6 consecutive years, with $27.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 30.83% year-over-year to $27.9 million, compared with a TTM value of $112.9 million through Sep 2025, down 22.23%, and an annual FY2024 reading of $138.4 million, up 6.1% over the prior year.
  • Research & Development was $27.9 million for Q3 2025 at Autolus Therapeutics, up from $27.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $40.3 million in Q3 2024 and bottomed at $26.7 million in Q1 2025.
  • Average Research & Development over 4 years is $32.3 million, with a median of $30.8 million recorded in 2024.
  • The sharpest move saw Research & Development rose 24.77% in 2024, then plummeted 30.83% in 2025.
  • Year by year, Research & Development stood at $37.6 million in 2022, then fell by 0.24% to $37.5 million in 2023, then decreased by 17.88% to $30.8 million in 2024, then fell by 9.53% to $27.9 million in 2025.
  • Business Quant data shows Research & Development for AUTL at $27.9 million in Q3 2025, $27.4 million in Q2 2025, and $26.7 million in Q1 2025.